Bayer (BAYN) Given Buy Rating at DZ Bank
Bayer (FRA:BAYN)‘s stock had its “buy” rating restated by DZ Bank in a report released on Friday.
BAYN has been the subject of a number of other reports. Sanford C. Bernstein set a €131.00 ($161.73) price objective on Bayer and gave the stock a “buy” rating in a report on Wednesday, November 29th. UBS Group set a €125.00 ($154.32) price objective on Bayer and gave the stock a “buy” rating in a report on Monday, February 12th. Warburg Research set a €121.00 ($149.38) target price on Bayer and gave the company a “neutral” rating in a research note on Wednesday. Cfra set a €105.00 ($129.63) target price on Bayer and gave the company a “buy” rating in a research note on Friday. Finally, Barclays set a €100.00 ($123.46) target price on Bayer and gave the company a “sell” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. Bayer currently has an average rating of “Buy” and an average price target of €119.68 ($147.76).
Bayer (BAYN) opened at €93.46 ($115.38) on Friday. Bayer has a fifty-two week low of €92.50 ($114.20) and a fifty-two week high of €123.82 ($152.86). The stock has a market capitalization of $77,560.00 and a PE ratio of 25.12.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.